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KEY POINTS 
We report strategies to reprogram macrophages as novel approach to treat Multiple 
Myeloma mouse models using pro-M1 and blocking M2 signals 
MIF is upregulated in the BM microenvironment of MM patients and plays an 
autocrine role in protumoral MØ polarization through CD74 and CXCR7 
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Summary 
Tumor associated macrophages (TAM) are important components of the multiple 
myeloma (MM) microenvironment that support malignant plasma cell survival and 
resistance to therapy. It has been proposed that macrophages (MØ) retain the capacity 
to change in response to stimuli that can restore their antitumor functions. Here we 
investigated several approaches to reprogram MØ as a novel therapeutic strategy in 
MM. First, we found tumor-limiting and tumor-supporting capabilities for monocyte-
derived M1-like MØ and M2-like MØ, respectively, when mixed with MM cells, both in 
vitro and in vivo. Multicolor confocal microscopy revealed that MM associated MØ 
displayed a predominant M2-like phenotype in the bone marrow of MM patient 
samples, and a high expression of the pro-M2 cytokine macrophage migration 
inhibitory factor (MIF). To reprogram the pro-tumoral M2-like MØ present in MM 
towards anti-tumoral M1-like MØ we tested the pro-M1 cytokine GM-CSF plus 
blockade of the M2 cytokines M-CSF or MIF. The combination of GM-CSF plus the MIF 
inhibitor 4-IPP achieved the best reprogramming responses towards an M1 profile, 
both at gene and protein expression levels, as well as remarkable tumoricidal effects. 
Furthermore, this combined treatment elicited macrophage-dependent therapeutic 
responses in MM xenograft mouse models, which were linked to up-regulation of M1 
and reciprocal down-regulation of M2 macrophage markers. Our results reveal the 
therapeutic potential of reprogramming macrophages in the context of MM.  
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Introduction 
Multiple myeloma (MM) is an incurable hematologic neoplasia characterized by 
accumulation in the bone marrow (BM) of malignant plasma cells that produce 
monoclonal proteins and cause bone lesions, renal disease and immunodeficiency 
1
. 
Survival of malignant plasma cells is supported by interactions with the BM 
microenvironment (cells, extracellular matrix and soluble factors), where macrophages 
(MØ) represent an important component
2,3
. Tumor associated macrophages (TAM) 
and related myeloid-derived suppressor cells protect MM cells from spontaneous and 
chemotherapy-induced apoptosis, and provide an immunosuppressive 
microenvironment 
4,5
. In addition, TAM participate in complex paracrine loops with 
stromal and endothelial cells, promoting MM survival and angiogenesis through 
release of VEGF and vasculogenic mimicry 
6-8
. Indeed, several studies have shown that 
MM patients with high BM-MØ infiltration have poor prognosis
9,10
. In spite of their 
pro-tumoral actions, MØ in the myeloma niche display inherent tumoricidal potential 
as demonstrated by the use of anti-CD47 antibodies that block “don’t eat me” signals, 
and elicit MØ-mediated myeloma regression
11
. Moreover, Th1 activated-MØ are 
important effectors cells mediating anti-tumor CD4+ T-cell responses in myeloma 
models
12
. Interestingly, macrophage-activating immunotherapy using CD40 plus TLR 
ligation has shown clinical benefit in a MM murine model 
13
. 
MØ therefore have great plasticity and can differentiate into several functional 
states in response to microenvironmental signals 
14
. Using different activation stimuli 
in vitro, MØ have been classified into two major polarized states: M1-MØ refers to 
classically activated MØ by cytokines such as IFN-γ, tumor necrosis factor (TNF-α) or 
granulocyte–macrophage colony-stimulating factor (GM-CSF), whereas M2-MØ refers 
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to alternatively activated MØ by IL-4, IL-13 or IL-10 
15
. M1-MØ have remarkable 
tumoricidal activity through secretion of cytotoxic factors (type I interferons, TNF-α, 
reactive nitrogen and oxygen species (RNS/ROS)) and phagocytosis 
16,17
. Notably, M1-
MØ can initiate specific anti-tumor immune responses through high expression of the 
major compatibility complex (MHC) and costimulatory molecules for efficient antigen 
presentation and proinflammatory cytokines (IL12 and IL23) to stimulate cytotoxic T 
and NK cells 
18
. In contrast, M2-MØ generally show low RNS/ROS production, low 
antigen-presentation and suppress antitumor immunity 
19
. 
Current in vivo evidence indicates that TAM are predominantly polarized 
towards the M2-like phenotype in advanced cancer stages, and that MØ targeting can 
be clinically beneficial 
14,19,20
. Rather than depletion of TAM, more targeted therapies 
are directed to block the pro-tumor functions of TAM, while promoting their anti-
tumor activities 
21
. Such reprogramming from M2-like to M1-like MØ may control 
inflammation-related cancer progression and elicit tumor-destructive reactions. 
Several factors can induce the M2-MØ phenotype including macrophage-colony 
stimulating factor (M-CSF) and macrophage migration inhibitory factor (MIF), both 
abundantly produced in tumors 
20,22,23
. M-CSF is crucial for MØ differentiation and 
survival, and inhibition of its signaling ablates TAM in mouse tumor models and is 
associated with clinical benefit in patients
20,24
 . MIF is strongly upregulated in tumors 
and is related to tumor progression and high clinical stage 
25,26
.  Furthermore, MIF-
deficient models of melanoma and chronic lymphocytic leukemia (CLL) displayed 
prolonged survival 
22,27
.  
In this study we have characterized the functions of M1-MØ compared to M2-
MØ in MM and have explored possible therapeutic protocols targeting MØ in 
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myeloma. Using a new double strategy that combines GM-CSF and antagonizes MIF 
signaling, we have reprogrammed TAM and showed therapeutic benefit in MM 
xenograft models.  Furthermore, we have defined the role of MIF and its receptors, 
CD74 and CXCR7 in M2-MØ polarization. 
Materials and Methods 
Patient samples, macrophages and MM cell lines. Samples from MM patients were 
obtained after informed consent and followed the guidelines from the Ethics 
Committees of Instituto de Investigación Sanitaria Gregorio Marañón, Hospital 12 de 
Octubre and Consejo Superior de Investigaciones Científicas. Patient characteristics are 
reported in Supplemental Table 1. CD138
+
 primary myeloma cells were purified from 
the mononuclear fraction of BM samples from patients with active MM using CD138 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Human monocytes were 
purified from buffy coats and differentiated to M1-like or M2-like MØ using GM-CSF or 
M-CSF, respectively, as previously reported 
28
 (protocol in Supplemental Figure 1E). 
Hereafter, we will refer to these phenotypes as GM-MØ and M-MØ, respectively. 
Human MØ and MM cell lines (NCI-H929, U266, MM.1S and MM.1S-GFP) were 
maintained in RPMI-1640 medium/10% fetal calf serum (Sigma-Aldrich, St. Louis, MO, 
USA) at 37ºC in 5% CO
2
/95% air atmosphere.  
For M-MØ reprogramming, the supernatant of previously differentiated M-MØ was 
replaced with fresh medium containing reprogramming agents (provided in 
Supplemental Table 2) every two days for seven additional days, as indicated in 
reprogramming protocol (Supplemental Figure 2A). 
MØ and MM cell co-cultures. MM cells were co-cultured with GM-MØ, M-MØ or 
reprogrammed MØ at 1:1 MØ/MM ratio. After 3 days, MM cell death was analyzed by 
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flow cytometry, using the Annexin V/Propidium Iodide kit (BD Bioscience, CA, USA). 
Staining with CD14Ab was used to exclude MØ from the analysis. MM cell proliferation 
was measured using carboxyfluorescein diacetate succinimidyl ester (CFSE, Life 
Technologies) and MØ and dead cells were excluded from this analysis using CD14Ab 
and 7-AAD staining, respectively.  
For non-cell-cell contact experiments, MØ were differentiated in the lower chamber of 
0.4 µM pore size Transwell inserts. MM cells were added to the upper chamber of the 
insert and MM cell death was determined after 3 days of culture. For experiments with 
conditioned media, the supernatants from various types of MØ or from GM-MØ+MM 
co-cultures were collected and added to MM cells (50% v/v). MM cell death analyses 
were performed after 3 days of culture. Conditioned media inactivation was 
performed by heating supernatants at 100ºC during 10 minutes. 
Other methods. Other methods, reagents and antibodies are provided in 
Supplemental Methods and Table 3. 
Results 
Differential role of polarized MØ on MM cell survival, proliferation and tumor 
growth. 
To determine the tumoricidal potential of polarized MØ towards MM cells, human 
monocytes were treated with either GM-CSF or M-CSF, to generate M1-like (GM-MØ) 
and M2-like (M-MØ) MØ, respectively. Phenotypical analyses confirmed that M-MØ 
had higher protein or mRNA expression of the M2 markers CD163, folate receptor beta 
(FRβ, encoded by FOLR2), STAB1, SERPINB2 and CCL2, and lower expression of the M1 
markers ICAM3, EGLN3, INHBA and MMP12 than GM-MØ 
29-33
(supplemental Figure 
1A). GM-MØ and M-MØ from 6 independent donors were co-cultured with several 
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MM cell lines and subsequently analyzed by flow cytometry, using annexin V and 
propidium iodide (AnV/PI) to identify dead MM cells and CD14 to exclude MØ (Figure 
1A and representative MØ donor in Supplemental Figure 1B). MM cells co-cultured 
with GM-MØ showed enhanced cell death compared with MM-cells cultured alone or 
co-cultured with M-MØ (Figure 1A). M-MØ also supported resistance of MM cells to 
the cytotoxic agent bortezomib (Figure 1B). Moreover, M-MØ protected primary MM 
cells from spontaneous death in ex vivo cultures, while GM-MØ enhanced basal cell 
death by 50% (Figure 1C).   
We next used video-microscopy to monitor MM cells in co-culture with MØ. 
During the first hours of co-culture with GM-MØ a significant number of NCI-H929 MM 
cells showed either rapid AnV+/PI+ staining (necrotic cell death) or long-lasting 
membrane blebbing and cell shrinkage (apoptotic cell death) (Figure 1D and 
supplemental video 1), indicating that GM-MØ were able to induce both forms of 
programmed cell death. By contrast, there were no dead MM cells in M-MØ+MM cell 
co-cultures or MM cells cultured alone (Figure 1D and supplemental video 2).  
To analyze the role of MØ on MM cell proliferation, we used CFSE dilution to 
monitor cell division of live MM cells (7-AAD negative). Figure 1E shows a progressive 
decrease in cell fluorescence in MM cells co-cultured with M-MØ, indicating active MM 
cell proliferation. MM cells co-cultured with GM-MØ maintained high CFSE-staining 
while MM cells cultured alone showed intermediate CFSE-staining (Figure 1E). These 
results indicated that M2-MØ enhance cell proliferation whereas M1-MØ do not. 
We next used a MM cell-xenograft model to examine whether human MØ 
could impact on tumor development. NCI-H929 cells were mixed with either GM-MØ 
or M-MØ and injected subcutaneously into NSG-mice. Determination of tumor size 
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revealed that MM cells co-injected with M-MØ developed larger tumors than when co-
injected with GM-MØ (Figure 1F). MM cells injected alone developed intermediate size 
tumors. Tissue analysis revealed a major component of CD38+/CD138+ tumor cells 
with scattered mouse and human MØ in both tumors (Figure 1G, quantified in 
Supplemental Figure 1C). Interestingly, MM+GM-MØ tumors displayed enhanced 
active caspase 3 levels, whereas MM+M-MØ showed higher Ki67 staining, revealing 
inverse apoptosis/proliferation ratio in each tumor. Comparable results were obtained 
when either GM-MØ or M-MØ were injected into the tumor at a later stage (after 
tumor volume reached 100 mm
3
) (Supplemental Figure 1D). These data indicate that 
M-MØ enhance and GM-MØ suppress MM tumor growth in vivo. 
Distinct response of polarized MØ in the secretion of cytotoxic factors and cross-
activation by MM cells 
To account for differences in macrophage differentiation protocols, we further 
exposed GM-MØ to LPS and IFN-γ (LPS/IFN-MØ), whereas M-MØ were treated with IL-
4 (IL4-MØ) (see protocol in supplemental Figure 1E). LPS/IFN-MØ displayed enhanced 
tumoricidal effect towards NCI-H929, but not towards U266 and MM.1s cells, 
compared with GM-MØ (Figure 2A). This indicates that further activation of GM-MØ 
with IFN-γ and LPS potentiates their killer ability towards certain MM cell lines. 
To determine whether the tumoricidal activity of MØ towards MM cells 
requires cell-cell contact, we used Transwell inserts to separate MØ and MM cells 
during culture. GM-MØ, and to a larger extent LPS/IFN–MØ, retained significant 
tumoricidal ability in this system, whereas M-MØ did not alter MM cell viability (Figure 
2B). Furthermore, as Transwell inserts prevent phagocytosis, the data show that the 
differential behavior of GM-MØ and M-MØ was not due to their distinct ability to 
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engulf apoptotic/necrotic cells. These results indicated that MØ tumoricidal effect 
involved, at least partially, the secretion of cytotoxic factors, a potential candidate 
being TNF-α
34
. No TNF-α production was detected in GM-MØ, M-MØ or MM cell 
culture media (Figure 2C). Interestingly, co-culture of GM-MØ with NCI-H929 or U266 
MM cells induced TNF-α secretion, whereas no TNF-α was  detected in co-cultures of 
MM cells with M-MØ. Culture supernatants of activated LPS/IFN-MØ contained large 
amounts of TNF-α, and co-culture with NCI-H929 or U266 MM cells further up-
regulated its secretion (Figure 2C). Production of IL-12 was also monitored as this 
cytokine encompasses both innate and adaptive anti-tumor immunity
35
 . Similarly to 
TNF-α, GM-MØ did not produce IL-12, but this powerful anti-tumor cytokine was highly 
induced upon co-culture with MM cells or activation by LPS/IFN (Figure 2D). These 
experiments demonstrated cross-activation of GM-MØ in co-culture with MM cells, 
which induced production of TNF-α and IL-12, compared with the lack of these 
cytokines in M-MØ co-cultured with MM cells. To further explore the role of TNF-α in 
MØ-dependent MM cell death, we incubated the supernatants obtained from Figure 
2C with the TNF-α blocking-Ab infliximab, and performed cytotoxic assays with NCI-
H929 or U266 cells (cell lines sensitive and resistant to TNF-α induced cell death, 
respectively 
36
). Figure 2E shows that infliximab reduced NCI-H929 cell death when 
cultured with GM-MØ+MM cell supernatant. In contrast, U266 cells were killed by 
other cytotoxic factors sensitive to heat inactivation (Figure 2E).  
To avoid MØ-MM cell cross-talk, we performed experiments with GM-MØ 
conditioned media, which still induced cell death of NCI-H929 cells and to a lesser 
extent of U266 cells (Figure 2F). LPS/IFN–MØ media enhanced death of NCI-H929 cells 
but not of U266 cells. Altogether these data demonstrate the differential response of 
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M1-like MØ, compared to M2-like MØ, to secrete IL-12, TNF-α and other cytotoxic 
factors and to be cross-activated by MM cells. 
Expression of MØ polarization markers by MM-associated macrophages  
We next analyzed the in vivo polarization state of macrophages present in BM 
samples, highly infiltrated by CD38+/ CD138+ plasma cells, from active MM patients. 
Whole mounts of BM samples were stained with MØ polarization markers and 
analyzed by confocal microscopy 
37
. Initial identification of MØ was performed using a 
combination of CD68 and CD163 MØ markers (Figure 3A), finding high expression of 
CD163 and moderate of CD68 in MM-infiltrating MØ (Figure 3B). CD163+ MØ were 
gated to quantify relative fluorescence expression of M1 markers CLEC5A, TNF-α and 
EGLN3 and M2 markers CD209 and FRβ 
38
(Figure 3A). We quantified more than 3,000 
single cells in several cases and these analyses revealed that MM-associated MØ highly 
express CD163, CD209 and FRβ, whereas most MØ were negative for CLEC5A, TNF-α 
and EGLN3 (Figure 3B). With respect to cytokines known to drive M2-TAM polarization, 
we found that MIF, a cytokine secreted by MM cells, was highly detected in the BM 
microenvironment. Interestingly, MM TAM showed elevated expression of CD74, MIF 
high-affinity receptor 
39
. 
Pro-tumoral towards anti-tumoral MØ reprogramming  
We then explored strategies to functionally reprogram stablished pro-tumoral MØ into 
tumoricidal effector MØ by using pro-M1 stimuli in combination with blocking M2 
autocrine/paracrine signaling and subsequently monitored expression of M1/M2 
markers (see protocol and MØ viability in Supplemental Figure 2A, B). Treatment with 
GM-CSF alone induced upregulation of M1-associated genes and down regulation of 
most M2-associated genes (Figure 4A). However, the combination of GM-CSF with 
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blockade of M2-signaling using an anti-M-CSF neutralizing Ab, or blocking the M-CSF 
receptor with GW2580 or Ki20227 
40
 reduced the expression of M1 genes compared to 
GM-CSF treatment alone (Supplemental Figure 2C).  
It has been reported that MIF controls the alternative activation of tumor MØ 
in a melanoma mouse model 
22
, and we found high expression of MIF in the BM 
microenvironment (Figure 3). Quantification of MIF secretion showed that is 
abundantly produced by M-MØ as well as by MM cells (Supplemental Figure 2D). 
Therefore, our next strategy was to block autocrine/paracrine MIF production either 
with the suicide antagonist 4-iodo-6-phenyl-pyrimidine (4-IPP)
41
, with the allosteric 
inhibitor p425, also known as Chicago Sky Blue 6B (CSB) 
42
, or by knocking-down MIF 
using siRNA. 4-IPP alone or MIF silencing significantly repressed M2-associated genes, 
which were further reduced by combining 4-IPP or CSB with GM-CSF (Figure 4A and 
Supplemental Figure 2E and F).  Furthermore, GM-CSF treatment showed a 
cooperative effect when combined with 4-IPP or CSB enhancing M1 genes, in contrast 
to M-CSF signaling antagonists. These changes were stable enough to down-regulate 
the surface expression of FRβ and CD163, and to up-regulate the M1 marker ICAM3 
(Figure 4B).  
In addition to changes in receptor surface expression, MØ polarization is 
associated with a shift in energy metabolism, and the AMP-Activated Protein Kinase 
(AMPK) is central in this regulation 
43
. To analyze AMPK activity during M-MØ 
reprograming towards M1, we analyzed by western blot T172 phosphorylation levels 
linked to AMPK activation, which is higher in M-MØ than in GM-MØ (data not shown). 
Interestingly, treatment of M-MØ with either GM-CSF or 4-IPP decreased AMPK T172 
phosphorylation, and reduction was even higher by combining both treatments (Figure 
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4C). These data indicate that GM-CSF and 4-IPP strongly down-regulate AMPK activity 
in M-MØ, suggesting a pro-inflammatory metabolic shift that might favor their pro-
inflammatory functions 
44
. 
We next determined the tumoricidal ability towards MM cells of MØ 
reprogrammed by different stimuli. M-MØ reprogrammed with GM-CSF, 4-IPP or 
blocking M-CSF alone displayed significant tumoricidal ability. Notably, a remarkable 
increase in MM cell death was reached by reprogrammed MØ treated with the 
combination of GM-CSF plus inhibition of M-CSF or MIF signaling, which was also 
confirmed by video-microscopy (Figure 4D and Supplemental Figure 2G, H). 
Nonetheless, the combination of GM-CSF+4-IPP showed the largest cytotoxic effect 
towards MM cells (Figure 4D). Altogether, these results indicate that the combination 
GM-CSF+4-IPP was remarkably effective at reprograming M-MØ towards M1-like MØ, 
as assessed by gene and protein expression as well as by tumoricidal responses. In 
addition, these results suggest that combining pro-M1 plus anti-M2 treatments may 
synergize for a more efficient repolarization towards anti-tumoral M1-like MØ. 
CD74 and CXCR7 are the MIF receptors involved in MØ reprogramming  
Besides binding to the high-affinity receptor CD74, MIF interacts with the chemokine 
receptors CXCR4, CXCR7 and CXCR2 
45
. To further characterize the role of MIF in MØ 
polarization, we first analyzed the expression of these receptors on M-MØ. These 
macrophages highly expressed CXCR4 at the cell surface, whereas CXCR7, CXCR2 and 
CD74 showed a predominant intracellular distribution (Figure 5A). We next compared 
the ability of 4-IPP together with MIF receptor blocking antibodies or antagonists to 
reprogram M-MØ, alone or in combination with GM-CSF. Interestingly, the anti-CD74 
Ab, the CXCR7-antagonist CCX733 and 4-IPP strongly reduced the expression of the 
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M2-specific FOLR2 gene (Figure 5B, left). Blocking CXCR2 or CXCR4 was less effective, 
suggesting that MIF was preferentially signaling through CD74 and CXCR7 to repolarize 
M2 macrophages. 4-IPP or the anti-CD74 Ab only mildly affected the expression of the 
M1-genes (Figure 5B). Importantly, the combination of GM-CSF with 4-IPP, or with 
CD74/CXCR7 inhibitors further enhanced M1-gene expression compared with GM-CSF 
alone (Figure 5B).  
Therapeutic evaluation of MØ reprogramming in a MM xenograft model  
The above data indicate that MIF is highly detected in the BM microenvironment of 
MM patient samples (Figure 3), and our in vitro results established that the most 
effective treatment for reprogramming M2-MØ towards M1-MØ was the GM-CSF+4-
IPP combination (Figure 4). Therefore, we evaluated the potential therapeutic 
application of this MØ reprogramming combination in NCI-H929 and MM.1S xenograft 
tumor mouse models. Previously, we confirmed that M-MØ and GM-MØ derived from 
NSG mice behave similarly to human MØ and that M-MØ repolarized with GM-CSF+4-
IPP displayed tumor cytotoxic activity in vitro (Supplemental Figure 2 I-J). For the NCI-
H929 xenografts, cells were subcutaneously injected into NSG and SCID mice, and 
when tumor volumes reached approximately 100 mm
3
, mice were treated with GM-
CSF+4-IPP, 4-IPP alone or vehicle. Significant reductions in NCI-H929 tumor volumes 
were observed in both murine models treated with GM-CSF+4-IPP, as compared to 
control mice or to 4-IPP alone (Figure 6 A). This was not due to MM toxicity, since our 
in vitro experiments demonstrated that 4-IPP was not toxic for MM cells 
(Supplemental Figure 2 K). To assess the specific contribution of MØ in the reduction of 
MM tumor sizes in mice treated with GM-CSF+4-IPP, we used clodronate-containing 
liposomes (clo-liposomes) to deplete MØ before the treatment. Subcutaneous NCI-
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H929 tumors did not develop if clo-liposomes were administered at the time of tumor 
injection (day 0, data not shown). Therefore, tumors were allowed to develop and 
mice were injected intravenously with clo-liposomes when tumors reached 100 mm
3
. 
In a preliminary experiment, we observed a significant reduction in TAM 48 hrs after 
clo-liposome administration (data not shown), therefore GM-CSF+4-IPP treatment was 
initiated at that time after clo-liposome infusion. Mice treated with GM-CSF+4-IPP 
developed smaller tumors and survived longer, compared with mice treated with clo-
liposomes plus GM-CSF+4-IPP (Figure 6B), suggesting that the presence of MØ during 
GM-CSF+4-IPP treatment is required for the therapeutic benefit against myeloma. 
To further characterize the in vivo reprogramming ability of GM-CSF+4-IPP treatment 
on SCID murine TAM, tumor-associated myeloid cells were isolated with CD11b 
magnetic beads from NCI-H929 tumors to quantify the relative expression of a panel of 
M1 and M2 mouse MØ genes 
46
. These analyses revealed a general reduction of M2 
markers on treated mice, which was statistically significant for Cd206, S1pr1, Stab1 and 
Ctla2b, and was associated with a reciprocal increase in M1-markers, including Inhba 
and Ccr2 compared with tumor-bearing control mice (Figure 6C).  
For the MM.1S xenograft model, we injected MM.1S-GFP
+ 
cells intravenously into NSG 
mice and after 10 days animals were treated every two days with GM-CSF+4-IPP or 
vehicle. Upon 2 weeks of treatment, MM.1S infiltration in the BM was quantified by 
flow cytometry and by mRNA expression of human GAPDH. The data revealed a 
significant reduction in MM.1S BM infiltration in GM-CSF+4-IPP treated mice (Figure 
6D-E), which was linked to a decrease in the expression of M2-markers and to an 
increase in M1-markers, as compared to vehicle (Figure 6F). These data indicate that 
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GM-CSF+4-IPP treatment reprograms gene expression of TAM in vivo, and generates a 
population of MØ with anti-tumoral properties.  
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Discussion 
MM remains an incurable malignancy mainly due to minimal residual disease, which is 
commonly supported by the BM microenvironment, leading to drug resistance and 
disease relapse 
47
. Therefore, new therapeutic strategies that target the supportive 
microenvironment are urgently needed to boost the efficacy of tumor-directed 
therapies. TAM represent an abundant component of BM microenvironment that 
contribute to MM cell resistance to conventional chemotherapy 
4,48
. However, the 
inherent tumoricidal potential of these MØ has not been explored. In the current study 
we evaluated for the first time the therapeutic value of reprogramming MØ in MM. 
We found that MIF is highly expressed in the BM microenvironment and plays an 
autocrine role in M2-MØ polarization through CD74 and CXCR7. Using a combined 
treatment to reprogram MM TAM with the pro-M1 cytokine GM-CSF plus blocking the 
pro-M2 cytokine MIF with 4-IPP, we induced up-regulation of M1-markers and the 
reciprocal down-regulation of M2-markers, both in vitro and in vivo. This combined 
treatment induced MØ-dependent tumor reduction in MM xenograft models, thus 
identifying MM-MØ as promising therapeutic targets. Furthermore, our data establish 
the translational potential of combining treatments that promote M1 while 
simultaneously blocking M2 signaling to re-educate TAM.  
We previously described M1 and M2 polarization markers for phenotyping 
tissue macrophages by multicolor confocal microscopy in several human pathologies 
38
. Our quantitative image analyses at the single-cell level revealed that TAM from 
active MM patients have a predominant M2-like phenotype. During tumor evolution a 
diverse spectrum of MØ populations develop within the tumor compartment 
49
. At 
patient early diagnosis, MM monocytes/macrophages display a pro-inflammatory 
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transcriptional profile in the MM microenvironment that leads to transcription of 
inflammatory cytokines 
6,50
. Interestingly, a shift towards M2 polarization occurs upon 
tumor progression in MM animal models 
50
, which is consistent with our results. 
Indeed, it was recently reported that the levels of soluble CD163 and CD206 (M2-MØ 
markers) present in serum are independent markers of overall survival in MM patients 
51,52
. In addition, we explored other factors reported to control TAM alternative 
activation such as MIF, which was selected because it is highly expressed by primary 
malignant plasma cells 
22,53
. Accordingly, we found abundant MIF in the MM BM 
microenvironment, along with high expression of the MIF receptor CD74 in MM TAM 
in patient samples. MIF was originally identified as a pro-inflammatory stimulus  
mainly produced by macrophages, which are able to secrete large amounts of this 
cytokine in response to various stimuli 
54
. Nevertheless, MIF is a pleiotropic cytokine 
with complex context-dependent signaling that leads to inhibition of anti-tumor 
reactivity in vivo 
55
. Furthermore, MIF controls mature B-cell proliferation and survival, 
and the humanized anti-CD74 monoclonal antibody milatuzumab is being clinically 
evaluated for treatment of multiple myeloma 
56
. Thus, blocking MIF or its receptors 
may target both, MM cells and macrophages in the BM microenvironment. The dual 
targeting of MM cells and the BM microenvironment is accomplished by novel 
therapies such as bortezomib, thalidomide and lenalidomide, that have significantly 
improved patient survival 
57
.  
As stated above, our goal was to re-program the M2-like MØ present in the 
MM microenvironment to become anti-tumoral M1-like MØ. To this end, we first 
analyzed the tumoricidal or supportive effects of diverse MØ polarization states 
towards MM cell lines. Interestingly, M1-like GM-MØ promoted both apoptotic and 
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necrotic forms of programmed cell death to MM cells and limited the growth of MM 
xenografts in vivo. On the other hand, M-MØ protected MM cells from bortezomib-
induced death in vitro and promoted tumor growth in vivo. Moreover, our previous 
results showed that M-MØ exhibit a gene profile similar to ex vivo-isolated TAMs from 
several tumor types 
58
, therefore supporting the use of M-MØ as an in vitro TAM 
model to explore reprogramming protocols.  
Reprogramming M-MØ with the pro-M1 cytokine GM-CSF induced low 
tumoricidal ability compared with GM-MØ programmed from monocytes, indicating 
that M-MØ are not as plastic as monocyte precursors. To reinforce MØ 
reprogramming, it is important to block autocrine/paracrine M2 signals, such as M-CSF 
or MIF, which are abundant in tumor microenvironments and might reverse the 
reprogrammed “therapeutic” M1-MØ 
19
. Inhibition of M-CSF signaling was one of the 
first TAM targetting strategies, which diminished M2-like MØ programming in 
glioma
59
. However,  blocking M-CSF signaling in combination with GM-CSF to 
reprogram MØ reduced INHBA expression, which encodes Activin A that is a key factor 
driving GM-CSF-dependent M1 polarization
33
. Interestingly, blocking MIF in 
combination with GM-CSF showed great induction of INHBA expression. MIF has been 
recently recognized as a pro-M2 tumor derived factor, whose disruption improved 
survival in chronic lymphocytic leukemia and melanoma mouse models 
22,27
. Our 
current results extend the role of MIF in M2 polarization from rodent to human 
macrophages and identify CD74 and CXCR7 as the main receptors for MIF involved in a 
pro-M2-MØ positive feed-back mechanism. 
Because single pro-M1-MØ or anti-M2-MØ agents had a partial effect in MØ 
reprogramming, we reasoned that the combination of both treatments may have a 
 19
synergistic effect. Indeed, treatment with GM-CSF and the MIF-inhibitor 4-IPP showed 
the best cooperative M1 to M2 shift at gene, protein and functional levels. 
Importantly, we demonstrated therapeutic benefit of this novel combination in mouse 
models of MM that were dependent on macrophages. Furthermore, TAM isolated 
from treated mice displayed enhanced M1 and diminished M2 gene expression. 
Altogether our results indicate that MØ-reprogramming strategies may provide 
significant clinical benefit for MM patients. 
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Figure Legends 
Figure 1. M1-MØ are cytotoxic to MM cells and inhibit MM cell proliferation and 
tumor development in vivo.  A) The indicated MM cell lines were cultured alone or in 
the presence of GM-MØ or M-MØ for 3 days. Cell death was measured and normalized 
by MM cell spontaneous death. Data represent mean±SEM of 6 independent 
experiments with different MØ donors. B) MM cells were cultured for 72h in the 
absence or presence of M-MØ, and cell death was induced with bortezomib (10 nM) 
(n=3 MØ donors). C) Cell death analysis of patient CD138+ MM BM cells (dot plot) 
cultured alone or with GM-MØ or M-MØ (48 h). D) NCI-H929 cells were co-cultured 
with GM-MØ or M-MØ (stained with CFSE; blue) and live-imaged for 4h. First and last 
frames are shown (bright field images). Rapid acquisition of AnV (green)/PI (red) 
staining represent necrotic cells (red circles). Blebbing-apoptotic cells are circled in 
yellow and one magnified case is indicated (asterisks). E) MM cell proliferation (CFSE 
dilution method) in the presence of GM-MØ or M-MØ. A representative experiment is 
shown on the left, and mean fluorescence intensity (MFI) values of 3 independent MØ 
donors normalized by NCI-H929 cultured alone, are shown on the right. F-G) NCI-H929 
cells were injected (s.c) alone or mixed with GM-MØ or M-MØ (1:1) in the flank of NSG 
mice. After 10 days mice were sacrificed for tumor volume evaluation (F) and confocal 
microscopy analysis (G) by determining CD138/CD38, caspase 3, F4/80, CD163 and 
cd45, and Ki67 labelling. Percentage of proliferating (Ki67) and apoptotic cells (active 
caspase 3) along intratumoral areas is represented on the right. Data show media±SEM 
of at least 4 mice per group (*, p<0.05; **, p<0.01, ***p<0.001).  
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Figure 2. M1-MØ and M2-MØ secretion of cytotoxic factors and cross-activation in 
co-culture with MM cells. A-B) MM cell death was analyzed after 72 h of co-culture of 
MM cells alone or in the presence of various types of the indicated MØ, in cell-cell 
contact experiments (A) and non-cell-cell contact Transwell experiments (B). C-D) 
Determination by ELISA of TNFα (C) and IL-12 p40 (D) levels in supernatants collected 
after 48h culture of various types of the indicated MØ, MM cell lines or MM+MØ co-
cultures. E) NCI-H929 and U266 cells were cultured with TNFα (200 ng/ml) or 
supernatants collected from GM-MØ+NCI-H929 and GM-MØ+U266 co-cultures, 
respectively (measured in C), and treated with infliximab (80 μg/ml), as indicated. GM-
MØ+MM conditioned media was inactivated by heat (10 minutes at 100ºC). F) 
Conditioned media of various types of the indicated MØ were collected and added to 
NCI-H929 or U266 cells (50% v/v). MM cell death was measured after 72 h of culture. 
Summarized results of at least three independent experiments with different donors 
±SEM are shown. (*, p<0.05; **, p<0.01, ***p<0.001). 
Figure 3. Phenotyping of MM- MØ from BM patient samples. A) Multi-colored 
staining of BM aspirates containing particles from active disease MM patients, as 
indicated. Upper panels represent panoramic views, while bottom panels are 
magnified ones. Nuclear-Dapi appears in blue in all cases. B) Plot showing the mean 
fluorescence intensity for each marker in CD163+ TAM (n=10 cases). Cells >25 arbitrary 
units (a.u) are considered positive, relative to negative control. Scale bars, as indicated. 
Figure 4. Repolarization of pro-tumoral M-MØ towards anti-tumoral MØ. A) RT-qPCR 
analyses of M2 and M1 genes from M-MØ treated for 24 hours with GM-CSF (1000 
U/ml), the MIF inhibitor 4-IPP (50 μM), or in combination. Values of M-MØ in the 
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absence of treatment are given an arbitrary value of 1. Results represent mean±SEM of 
10 independent donors. B) Flow cytometry histograms showing cell surface expression 
of FRβ, CD163 and ICAM-3 in M-MØ untreated or treated as indicated. Results from a 
representative MØ donor (upper graphs), and MFI±SEM quantification of at least 4 
independent experiments with the indicated treatments (lower graphs) are shown. 
Values in the absence of treatment are given an arbitrary value of 1. C) Immunoblot 
analysis of P-AMPK expression in M-MØ untreated or treated for 6 hours with GM-CSF, 
4-IPP or in combination. Densitometric analyses (arbitrary units, a.u) normalized to 
GAPDH levels and referred to M-MØ control are shown. D) Determination of NCI-H929 
and U266 cell death alone (first bar) or cultured with M-MØ untreated or treated as 
indicated. 4-IPP (50 μM), M-CSF neutralizing antibody (1μg/ml), M-CSFr inhibitor 
GW2580 (1μM). Results represent mean ±SEM of 3 independent experiments with 
different donors (*, p<0.05; **, p<0.01, ***p<0.001). 
Figure 5. MIF receptors and signaling during MØ repolarization. A) Flow cytometry 
analyses of intracellular and surface expression of MIF receptors CXCR4, CXCR7, CXCR2 
and CD74 on M-MØ. B) Expression levels of FOLR2, INHBA and EGLN3, as determined 
by RT-qPCR on M-MØ treated for 24 hours with GM-CSF (1000 U/ml); 4-IPP (50 μM); 
AMD3100 (25 μg/ml); CCX733 (100 nM); SB225002 (300 nM) and α-CD74 blocking 
antibody (5 μg/ml); or GM-CSF in combination with all of them. Values in the absence 
of treatment are given an arbitrary value of 1. Result represents mean ±SEM of 4 
independent donors. (*, p<0.05; **, p<0.01, ***p<0.001) 
Figure 6. GM-CSF+4-IPP therapeutic effect in immunodeficient mice MM xenograft 
models. A) NCI-H929 cells were s.c inoculated into the flank of NSG (left graph) or SCID 
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mice (right graph). When tumors reached volumes of 100 mm
3
, mice were treated 
every two days until sacrifice (day 18
th
) with the indicated treatments. (Left, n=6-10 
per group; right, n=8). B) NSG mice displaying 100 mm
3 
subcutaneous NCI-H929 
tumors were injected i.v with clodronate, and two days later, mice were treated with 
GM-CSF+4-IPP every two days. Tumor growth was measured daily. Data show tumor-
volume average of 5 mice per group ±SEM. C) M1 and M2 polarization murine marker 
expression in CD11b+ cells isolated from tumors grown in SCID mice, as determined by 
RT-qPCR (n=10). Relative expression (log scale) indicates the expression of each marker 
after GM-CSF+4-IPP treatment relative to its expression in the absence of treatment. 
D-E) MM.1S-GFP cells were i.v. injected into NSG mice and 10 days later mice were 
treated with GM-CSF/4-IPP or with vehicle. Mice were sacrificed after 2 weeks of 
treatment, and BM cells were analyzed by flow cytometry for human HLA-1 and GFP 
expression. Representative dot-plots panels showing HLA-1+/GFP+ percentages (left), 
and quantification of BM infiltration (right) are displayed. (B) RT-qPCR analyses of 
human GAPDH expression of BM samples from vehicle- or GM-CSF/4-IPP-treated mice. 
Data show the mean±SEM of 14 mice. F) M1 and M2 polarization murine marker 
expression in the BM from NSG mice infiltrated with MM.1S-GFP cells, shown as in C. 
(*, p<0.05; **, p<0.01, ***p<0.001).  
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